A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.

A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer containing trastuzumab temsirolimus and/or HKI-272 optionally in combination with other anti-neoplastic agents or immune modulators are described.

A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per week. In some embodiments of the invention the tivozanib is administered on a repeating schedule of one dose per day for three weeks followed by one week without tivozanib administration. The disclosed method is particularly suitable for treatment of renal cell carcinoma.

The instant invention provides methods of treating breast cancer in a subject suffering there from comprising administering a therapeutically effective amount of an mTor inhibitor an anti-IGF-IR antibody and an aromatase inhibitor. In one embodiment of the methods of the invention the mTOR inhibitor is rapamycin a rapamycin analog selected from ridaforolimus everolimus or temsirolimus or a combination thereof. In another embodiment of the methods of the invention the anti-IGF-1 R antibody is sel...

Disclosed are methods for treating a patient with an mTOR inhibitor such as AP23573 sirolimus temsirolimus everolimus etc.

A method for preparing temsirolimus the method including: using a substituted aromatic aldehyde to protect 22-dimethylol propionic acid to produce intermediate II; carrying out reaction between the intermediate II and 246-trichlorobenzoyl chloride; carrying out condensation reaction between a resulting product and rapamycin to produce intermediate III; and finally using sulfuric acid to remove a protecting group from the intermediate III to yield temsirolimus.

A method for synthesizing temsirolimus the method including: using a substituted boric acid to protect 22-dimethylol propionic acid to produce intermediate II; carrying out a reaction between the intermediate II and 246-trichlorobenzoyl chloride; carrying out condensation reaction between a resulting product and rapamycin to produce intermediate III; and finally using a diol to remove a protecting group from the intermediate III to yield temsirolimus.

A method for preparing temsirolimus, the method including: using a substituted aromatic aldehyde to protect 2,2-dimethylol propionic acid to produce intermediate II